Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel.
about
Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cellsIntelligent design: combination therapy with oncolytic virusesOncolytic adenovirus-mediated therapy for prostate cancerOncolysis and suppression of tumor growth by a GFP-expressing oncolytic adenovirus controlled by an hTERT and CMV hybrid promoter.Potent anti-tumour activity of a novel conditionally replicating adenovirus for melanoma via inhibition of migration and invasion.Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging.Advances in preclinical investigation of prostate cancer gene therapy.A novel approach for detecting viable and tissue-specific circulating tumor cells through an adenovirus-based reporter vector.Combinatory cytotoxic effects produced by E1B-55kDa-deleted adenoviruses and chemotherapeutic agents are dependent on the agents in esophageal carcinoma.Developing novel oncolytic adenoviruses through bioselectionEnhanced antitumor activity by combining an adenovirus harboring ING4 with cisplatin for hepatocarcinoma cellsChemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer.Anti-tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice.Soluble vascular endothelial growth factor decoy receptor FP3 exerts potent antiangiogenic effectsConditionally replicating adenoviruses for cancer treatment.Adenoviral vector-based strategies for cancer therapy.Bugs and drugs: oncolytic virotherapy in combination with chemotherapy.Combination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models.Targeted and armed oncolytic adenovirus via chemoselective modification.Theranostic potential of oncolytic vaccinia virus.A new type of adenovirus vector that utilizes homologous recombination to achieve tumor-specific replicationVerapamil enhances the antitumoral efficacy of oncolytic adenoviruses.Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells.E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models.Chemovirotherapy of Pancreatic Adenocarcinoma by Combining Oncolytic Vaccinia Virus GLV-1h68 with nab-Paclitaxel Plus Gemcitabine.Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin.Synergistic inhibition of tumor growth by combination treatment with drugs against different subpopulations of glioblastoma cells.Designer Oncolytic Adenovirus: Coming of Age.Improving adenoviral vectors and strategies for prostate cancer gene therapy
P2860
Q21245717-94157FC2-18F6-4575-B1BE-6269B102916FQ24628227-51FFA3DE-9351-4034-A281-04A3E7FBA5D7Q27004796-6A9D0A45-40EA-4DE6-BC93-09E134211777Q33234192-3A8C8666-7722-402A-93C4-739109DE1353Q33613626-0D55312F-71A7-4107-9E94-643D60A158F1Q33641230-2990F77F-39D9-4CCB-8B64-E9C09DF5FF2EQ33677054-94FC800D-EDF7-4895-A576-59DD7C4419EDQ34036427-B409794E-A8D9-4F97-B069-5FC686EA3DC4Q34238784-BA7823EB-1E3A-412D-B791-9E012F059134Q34471952-41257B3B-1E52-4161-A977-1D55428DCDA9Q34619830-62009B96-0FC7-4612-ACB6-811E1B26E79CQ34757261-9D5FDE9C-46D7-4638-B0F2-BFC4560CC2AEQ35157425-1282DD62-6315-4BF3-99F4-F115D1AB3095Q35939433-F82DEB06-EA47-4E05-885C-E3030CF4D14FQ35967313-8E3E7E90-B946-4EF1-ACAF-4A9F2085751BQ37409025-2AB961A5-293D-4BC7-97D9-0770BE3A9679Q37899223-CF22D6A6-D087-4981-9E4C-9C90DB113A7FQ39247534-7E2C4246-5C1B-4526-8D26-248027438AC2Q39525331-C5D2DB92-2D71-405C-8738-B071F18A5F39Q39628429-A995F1E0-C552-454D-9EE4-34F1C8026ED7Q39685348-F54E041B-69AF-44F8-ACD8-8143FD60502BQ39735941-0AB0B43E-68A8-4FDC-B624-4E11F03F8C77Q39745964-CBD980D5-1EB8-4098-B787-02464A3221BEQ40045957-24C4E77D-ED8B-42E2-9122-B877ECDBE389Q40162348-6452E8B4-F0E4-46EB-9AC2-61D7319E8980Q40273594-706E8F97-0833-4B50-8F10-1B4505FFB966Q47122552-AD80E258-3A7D-4D52-82F7-0BEF09BEBCBFQ55467684-6532D2CF-7A11-46B1-A3E2-98588EB3D4E7Q58801177-B32A2301-E36B-4808-9B28-536C2FE94A81
P2860
Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Antitumor synergy of CV787, a ...... and paclitaxel and docetaxel.
@ast
Antitumor synergy of CV787, a ...... and paclitaxel and docetaxel.
@en
type
label
Antitumor synergy of CV787, a ...... and paclitaxel and docetaxel.
@ast
Antitumor synergy of CV787, a ...... and paclitaxel and docetaxel.
@en
prefLabel
Antitumor synergy of CV787, a ...... and paclitaxel and docetaxel.
@ast
Antitumor synergy of CV787, a ...... and paclitaxel and docetaxel.
@en
P2093
P1433
P1476
Antitumor synergy of CV787, a ...... and paclitaxel and docetaxel.
@en
P2093
D R Henderson
P304
P407
P577
2001-01-01T00:00:00Z